Advanced Biliary Tract Carcinoma
Conditions
Keywords
Gemcitabine, Cisplatin, MEK162, 13-004
Brief summary
The purpose of this study is to test an investigational combination of drugs for bile duct or gallbladder cancers. Gemcitabine and cisplatin are two forms of chemotherapy commonly used in combination to treat bile duct and gallbladder cancers. The investigators are looking to improve treatment results. They will attempt to do so by adding the drug MEK162 to the treatment plan. MEK162 acts by blocking a protein called MEK 1/2 which helps cancer cells grow and divide. This study will help answer the question of whether MEK162 is a helpful drug in patients with bile duct or gallbladder cancers when given with gemcitabine and cisplatin.
Interventions
DRUGGemcitabine
DRUGCisplatin
DRUGMEK162
Sponsors
Array BioPharma
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically / cytologically verified, non-resectable, recurrent, or metastatic biliary tract carcinoma including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma and gallbladder carcinoma. Combined cholangiocarcinoma and hepatocellular carcinoma is allowed. * Patients must have measurable disease by RECIST 1.1 * KPS ≥ 80% * Age ≥ 18 years * Adequate bone marrow function defined as: Hb ≥ 8 g/dl, ANC ≥ 1.5 K/mcL, Platelets ≥ 100 K/mcL * Adequate renal function defined as serum creatinine \< 1.6 mg/dl and/or measured creatinine clearance from 24-hour urine collection of ≥ 60 ml/min * Adequate hepatic function defined as total bilirubin ≤ 2 mg/dl, ALT/AST ≤ 5 x ULN. * Patients with biliary obstruction can join if bilirubin corrects to required limit after adequate biliary drainage. Adequate cardiac function defined as ejection fraction ≥ 45% as determined by transthoracic echocardiogram or MUGA * Patients who have received prior local therapy, including but not limited to embolization, chemoembolization, radiofrequency ablation, radiation therapy, are eligible provided that measurable disease falls outside the treatment field or within the field but has shown an increase of ≥ 20% in the size. Prior local therapy must be completed at least 4 weeks prior to the baseline scan * Women of childbearing potential must have a negative pregnancy test within 7 days prior to study treatment * Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter. * Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Any previous chemotherapy, biologic therapy, or investigational agent, except for adjuvant therapy as single agents and/or as radio-sensitizing agents limited to 5-fluorouracil and gemcitabine. Patient must have completed adjuvant therapy no less than six months prior to accrual. * Evidence of another active cancer that may influence patient outcome as determined by the Principal Investigator (PI) or co-Principal Investigator (co-PI), except for nonmelanoma skin carcinoma, melanoma in-situ, in-situ carcinoma of the cervix curatively treated, treated superficial bladder cancer, and adenocarcinoma of the prostate that has been surgically treated with a post-treatment PSA that is non-detectable. * Known brain metastases or primary central nervous system tumors with seizures that are not well controlled with standard medical therapy. * Uncontrolled intercurrent illness including, but not limited to psychiatric illness/social situations that would limit compliance with study requirements. * Known HIV positive patient * Significant cardiovascular disease including congestive heart failure (New York Heart Association Class II or higher) or active angina pectoris. * History of a myocardial infarction within 6 months. * History of a stroke or transient ischemic attack within 6 months. * Clinically significant peripheral vascular disease. * Major surgical procedure within 4 weeks. * Uncontrolled infection. * Known or suspected allergy to gemcitabine or cisplatin * Pregnant (positive pregnancy test) * Breast-feeding should be discontinued if a nursing mother is to be treated on clinical trial. * Any condition that impairs patient's ability to swallow whole pills * Malabsorption problem that may limit or inhibit the absorption of MEK 162 * Patients with a history or current known evidence of central serous retinopathy (CSR), retinal vein occlusion (RVO) or ophthalmopathy at baseline that would be considered a risk factor for CSR or RVO. * History of any organ or bone marrow transplant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MTD of MEK162 - Phase I | 1 year | In the phase I portion, up to 18 patients will be enrolled in classic 3+3 cohort dose escalation design to identify the MTD of MEK162 when administered with gemcitabine and cisplatin given weeks 2 and 3 of a 3 week cycle . |
| Six-month Progression Free Survival | 6 months | An exact binomial single stage design will be used to discriminate between true 6-month PFS rates of 59% vs. 82%, and between true response rates of 26% and 50%. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions |
| Objective Response Rate (ORR) | 1 year | Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Median PFS | 1 year | progression free survival will be calculated from study entry to documented disease progression or death from any cause, whatever occurs first. |
| Median Overall Survival | 1 year | (survival) will be calculated from study entry to death or last follow up |
| Participants Evaluated for Toxicity | 2 years | All toxicities will be rated as per the NCI Common Toxicity Criteria, version 4. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1 Cohort 1 Phase I, Dose Level 1 - MEK162 25 mg | 3 |
| Cohort 2 Cohort 2 Phase I, Dose Level 2 - MEK162 45mg | 6 |
| Cohort 3 Cohort 3 Phase I, Dose Level 3 / Phase II - MTD mg | 3 |
| Cohort 4 Cohort 4 Phase II only, MTD mg | 29 |
| Total | 41 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Withdrawal by Subject | 0 | 0 | 0 | 1 |
Baseline characteristics
| Characteristic | Cohort 1 | Total | Cohort 4 | Cohort 3 | Cohort 2 |
|---|---|---|---|---|---|
| Age, Continuous | 64.3 years | 66 years | 69 years | 71.3 years | 54.3 years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 2 Participants | 37 Participants | 27 Participants | 3 Participants | 5 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 1 Participants | 4 Participants | 2 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 4 Participants | 2 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) White | 2 Participants | 36 Participants | 27 Participants | 2 Participants | 5 Participants |
| Region of Enrollment United States | 3 Participants | 41 Participants | 29 Participants | 3 Participants | 6 Participants |
| Sex: Female, Male Female | 2 Participants | 20 Participants | 13 Participants | 2 Participants | 3 Participants |
| Sex: Female, Male Male | 1 Participants | 21 Participants | 16 Participants | 1 Participants | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 2 / 3 | 4 / 6 | 1 / 3 | 16 / 29 |
| other Total, other adverse events | 0 / 0 | 0 / 0 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 1 / 3 | 1 / 6 | 3 / 3 | 29 / 29 |
Outcome results
Primary
MTD of MEK162 - Phase I
In the phase I portion, up to 18 patients will be enrolled in classic 3+3 cohort dose escalation design to identify the MTD of MEK162 when administered with gemcitabine and cisplatin given weeks 2 and 3 of a 3 week cycle .
Time frame: 1 year
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Gemcitabine, Cisplatin and MEK162 | MTD of MEK162 - Phase I | 45 mg |
Primary
Objective Response Rate (ORR)
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: 1 year
Population: 1 participant withdrew consent before starting treatment
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Gemcitabine, Cisplatin and MEK162 | Objective Response Rate (ORR) | 12 percentage of participants with ORR |
Primary
Six-month Progression Free Survival
An exact binomial single stage design will be used to discriminate between true 6-month PFS rates of 59% vs. 82%, and between true response rates of 26% and 50%. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions
Time frame: 6 months
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Gemcitabine, Cisplatin and MEK162 | Six-month Progression Free Survival | Progression free | 19 Participants |
| Gemcitabine, Cisplatin and MEK162 | Six-month Progression Free Survival | Progressed | 23 Participants |
Secondary
Median Overall Survival
(survival) will be calculated from study entry to death or last follow up
Time frame: 1 year
Population: 1 participant withdrew consent before starting treatment
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Gemcitabine, Cisplatin and MEK162 | Median Overall Survival | 13.3 months |
Secondary
Median PFS
progression free survival will be calculated from study entry to documented disease progression or death from any cause, whatever occurs first.
Time frame: 1 year
Population: 1 participants withdrew consent before received treatment
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Gemcitabine, Cisplatin and MEK162 | Median PFS | 6 months |
Secondary
Participants Evaluated for Toxicity
All toxicities will be rated as per the NCI Common Toxicity Criteria, version 4.
Time frame: 2 years
Population: 1 participants withdrew consent before receiving treatment
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Gemcitabine, Cisplatin and MEK162 | Participants Evaluated for Toxicity | Evaluated for toxicity | 41 Participants |
| Gemcitabine, Cisplatin and MEK162 | Participants Evaluated for Toxicity | Not evaluable/withdrew consent before treatment | 1 Participants |